Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound

Shigeki Kiyonaka, Kenta Kato, Motohiro Nishida, Kazuhiro Mio, Takuro Numaga, Yuichi Sawaguchi, Takashi Yoshida, Minoru Wakamori, Emiko Mori, Tomohiro Numata, Masakazu Ishii, Hiroki Takemoto, Akio Ojida, Kenta Watanabe, Aya Uemura, Hitoshi Kurose, Takashi Morii, Tsutomu Kobayashi, Yoji Sato, Chikara Sato & 2 others Itaru Hamachi, Yasuo Mori

Research output: Contribution to journalArticle

255 Citations (Scopus)

Abstract

Canonical transient receptor potential (TRPC) channels control influxes of Ca2+ and other cations that induce diverse cellular processes upon stimulation of plasma membrane receptors coupled to phospholipase C (PLC). Invention of subtype-specific inhibitors for TRPCs is crucial for distinction of respective TRPC channels that play particular physiological roles in native systems. Here, we identify a pyrazole compound (Pyr3), which selectively inhibits TRPC3 channels. Structure-function relationship studies of pyrazole compounds showed that the trichloroacrylic amide group is important for the TRPC3 selectivity of Pyr3. Electrophysiological and photoaffinity labeling experiments reveal a direct action of Pyr3 on the TRPC3 protein. In DT40 B lymphocytes, Pyr3 potently eliminated the Ca2+ influx-dependent PLC translocation to the plasma membrane and late oscillatory phase of B cell receptorinduced Ca2+ response. Moreover, Pyr3 attenuated activation of nuclear factor of activated T cells, a Ca2+-dependent transcription factor, and hypertrophic growth in rat neonatal cardiomyocytes, and in vivo pressure overload-induced cardiac hypertrophy in mice. These findings on important roles of native TRPC3 channels are strikingly consistent with previous genetic studies. Thus, the TRPC3- selective inhibitor Pyr3 is a powerful tool to study in vivo function of TRPC3, suggesting a pharmaceutical potential of Pyr3 in treatments of TRPC3-related diseases such as cardiac hypertrophy.

Original languageEnglish
Pages (from-to)5400-5405
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume106
Issue number13
DOIs
Publication statusPublished - Mar 31 2009

Fingerprint

Cardiomegaly
Type C Phospholipases
B-Lymphocytes
Cell Membrane
NFATC Transcription Factors
Transient Receptor Potential Channels
Cardiac Myocytes
Amides
Cations
Transcription Factors
Pressure
Growth
Pharmaceutical Preparations
Proteins
TRPC3 cation channel
pyrazole

All Science Journal Classification (ASJC) codes

  • General

Cite this

Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound. / Kiyonaka, Shigeki; Kato, Kenta; Nishida, Motohiro; Mio, Kazuhiro; Numaga, Takuro; Sawaguchi, Yuichi; Yoshida, Takashi; Wakamori, Minoru; Mori, Emiko; Numata, Tomohiro; Ishii, Masakazu; Takemoto, Hiroki; Ojida, Akio; Watanabe, Kenta; Uemura, Aya; Kurose, Hitoshi; Morii, Takashi; Kobayashi, Tsutomu; Sato, Yoji; Sato, Chikara; Hamachi, Itaru; Mori, Yasuo.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 106, No. 13, 31.03.2009, p. 5400-5405.

Research output: Contribution to journalArticle

Kiyonaka, S, Kato, K, Nishida, M, Mio, K, Numaga, T, Sawaguchi, Y, Yoshida, T, Wakamori, M, Mori, E, Numata, T, Ishii, M, Takemoto, H, Ojida, A, Watanabe, K, Uemura, A, Kurose, H, Morii, T, Kobayashi, T, Sato, Y, Sato, C, Hamachi, I & Mori, Y 2009, 'Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound', Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 13, pp. 5400-5405. https://doi.org/10.1073/pnas.0808793106
Kiyonaka, Shigeki ; Kato, Kenta ; Nishida, Motohiro ; Mio, Kazuhiro ; Numaga, Takuro ; Sawaguchi, Yuichi ; Yoshida, Takashi ; Wakamori, Minoru ; Mori, Emiko ; Numata, Tomohiro ; Ishii, Masakazu ; Takemoto, Hiroki ; Ojida, Akio ; Watanabe, Kenta ; Uemura, Aya ; Kurose, Hitoshi ; Morii, Takashi ; Kobayashi, Tsutomu ; Sato, Yoji ; Sato, Chikara ; Hamachi, Itaru ; Mori, Yasuo. / Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound. In: Proceedings of the National Academy of Sciences of the United States of America. 2009 ; Vol. 106, No. 13. pp. 5400-5405.
@article{93197f77f01f47a4a193a9b4cb880828,
title = "Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound",
abstract = "Canonical transient receptor potential (TRPC) channels control influxes of Ca2+ and other cations that induce diverse cellular processes upon stimulation of plasma membrane receptors coupled to phospholipase C (PLC). Invention of subtype-specific inhibitors for TRPCs is crucial for distinction of respective TRPC channels that play particular physiological roles in native systems. Here, we identify a pyrazole compound (Pyr3), which selectively inhibits TRPC3 channels. Structure-function relationship studies of pyrazole compounds showed that the trichloroacrylic amide group is important for the TRPC3 selectivity of Pyr3. Electrophysiological and photoaffinity labeling experiments reveal a direct action of Pyr3 on the TRPC3 protein. In DT40 B lymphocytes, Pyr3 potently eliminated the Ca2+ influx-dependent PLC translocation to the plasma membrane and late oscillatory phase of B cell receptorinduced Ca2+ response. Moreover, Pyr3 attenuated activation of nuclear factor of activated T cells, a Ca2+-dependent transcription factor, and hypertrophic growth in rat neonatal cardiomyocytes, and in vivo pressure overload-induced cardiac hypertrophy in mice. These findings on important roles of native TRPC3 channels are strikingly consistent with previous genetic studies. Thus, the TRPC3- selective inhibitor Pyr3 is a powerful tool to study in vivo function of TRPC3, suggesting a pharmaceutical potential of Pyr3 in treatments of TRPC3-related diseases such as cardiac hypertrophy.",
author = "Shigeki Kiyonaka and Kenta Kato and Motohiro Nishida and Kazuhiro Mio and Takuro Numaga and Yuichi Sawaguchi and Takashi Yoshida and Minoru Wakamori and Emiko Mori and Tomohiro Numata and Masakazu Ishii and Hiroki Takemoto and Akio Ojida and Kenta Watanabe and Aya Uemura and Hitoshi Kurose and Takashi Morii and Tsutomu Kobayashi and Yoji Sato and Chikara Sato and Itaru Hamachi and Yasuo Mori",
year = "2009",
month = "3",
day = "31",
doi = "10.1073/pnas.0808793106",
language = "English",
volume = "106",
pages = "5400--5405",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "13",

}

TY - JOUR

T1 - Selective and direct inhibition of TRPC3 channels underlies biological activities of a pyrazole compound

AU - Kiyonaka, Shigeki

AU - Kato, Kenta

AU - Nishida, Motohiro

AU - Mio, Kazuhiro

AU - Numaga, Takuro

AU - Sawaguchi, Yuichi

AU - Yoshida, Takashi

AU - Wakamori, Minoru

AU - Mori, Emiko

AU - Numata, Tomohiro

AU - Ishii, Masakazu

AU - Takemoto, Hiroki

AU - Ojida, Akio

AU - Watanabe, Kenta

AU - Uemura, Aya

AU - Kurose, Hitoshi

AU - Morii, Takashi

AU - Kobayashi, Tsutomu

AU - Sato, Yoji

AU - Sato, Chikara

AU - Hamachi, Itaru

AU - Mori, Yasuo

PY - 2009/3/31

Y1 - 2009/3/31

N2 - Canonical transient receptor potential (TRPC) channels control influxes of Ca2+ and other cations that induce diverse cellular processes upon stimulation of plasma membrane receptors coupled to phospholipase C (PLC). Invention of subtype-specific inhibitors for TRPCs is crucial for distinction of respective TRPC channels that play particular physiological roles in native systems. Here, we identify a pyrazole compound (Pyr3), which selectively inhibits TRPC3 channels. Structure-function relationship studies of pyrazole compounds showed that the trichloroacrylic amide group is important for the TRPC3 selectivity of Pyr3. Electrophysiological and photoaffinity labeling experiments reveal a direct action of Pyr3 on the TRPC3 protein. In DT40 B lymphocytes, Pyr3 potently eliminated the Ca2+ influx-dependent PLC translocation to the plasma membrane and late oscillatory phase of B cell receptorinduced Ca2+ response. Moreover, Pyr3 attenuated activation of nuclear factor of activated T cells, a Ca2+-dependent transcription factor, and hypertrophic growth in rat neonatal cardiomyocytes, and in vivo pressure overload-induced cardiac hypertrophy in mice. These findings on important roles of native TRPC3 channels are strikingly consistent with previous genetic studies. Thus, the TRPC3- selective inhibitor Pyr3 is a powerful tool to study in vivo function of TRPC3, suggesting a pharmaceutical potential of Pyr3 in treatments of TRPC3-related diseases such as cardiac hypertrophy.

AB - Canonical transient receptor potential (TRPC) channels control influxes of Ca2+ and other cations that induce diverse cellular processes upon stimulation of plasma membrane receptors coupled to phospholipase C (PLC). Invention of subtype-specific inhibitors for TRPCs is crucial for distinction of respective TRPC channels that play particular physiological roles in native systems. Here, we identify a pyrazole compound (Pyr3), which selectively inhibits TRPC3 channels. Structure-function relationship studies of pyrazole compounds showed that the trichloroacrylic amide group is important for the TRPC3 selectivity of Pyr3. Electrophysiological and photoaffinity labeling experiments reveal a direct action of Pyr3 on the TRPC3 protein. In DT40 B lymphocytes, Pyr3 potently eliminated the Ca2+ influx-dependent PLC translocation to the plasma membrane and late oscillatory phase of B cell receptorinduced Ca2+ response. Moreover, Pyr3 attenuated activation of nuclear factor of activated T cells, a Ca2+-dependent transcription factor, and hypertrophic growth in rat neonatal cardiomyocytes, and in vivo pressure overload-induced cardiac hypertrophy in mice. These findings on important roles of native TRPC3 channels are strikingly consistent with previous genetic studies. Thus, the TRPC3- selective inhibitor Pyr3 is a powerful tool to study in vivo function of TRPC3, suggesting a pharmaceutical potential of Pyr3 in treatments of TRPC3-related diseases such as cardiac hypertrophy.

UR - http://www.scopus.com/inward/record.url?scp=65249173997&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249173997&partnerID=8YFLogxK

U2 - 10.1073/pnas.0808793106

DO - 10.1073/pnas.0808793106

M3 - Article

VL - 106

SP - 5400

EP - 5405

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 13

ER -